Studying what predicts response to TNF-alpha inhibitor treatment in inflammatory bowel disease
Studies clinical features and biopsies in adults with ulcerative colitis or Crohn disease.
Plain-language title generated from the registry record
Registry title: Predictors of Prognosis in IBD Patients
Key facts
- Where
- Seongnam-si, South KoreaSee the site
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Bundang Hospital
- Trial code
- NCT05653011
- Record updated
- 24 April 2026
- Original description
A study of clinical characteristics and potential prognostic factors in inflammatory bowel diseaseRead full original descriptionShow less
Predictors of Response After Induction Therapy With TNF-alpha Inhibitor in Inflammatory Bowel Disease, Comparison to Normal
A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease
Inclusion: control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma); TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment; TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor.
Exclusion: Patients who were treated with antibiotics or probiotics within the last 3 months; Age under 18 years.